Physician profile
Timothy Yao
NPI 1760712699
$2,710.55
in general payments reported to CMS, 2019-2025
27 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $699 · 2023: $917 · 2024: $255 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,046.03 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $536.12 | 2021-2023 | Korlym |
| Lilly USA, LLC | $174.71 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Mannkind Corporation | $171.98 | 2021-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $73.87 | 2025 | Gvoke Hypopen |
| Novo Nordisk INC | $63.08 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $60.09 | 2023-2025 | Prolia, Evenity, Repatha |
| Dexcom, INC. | $59.32 | 2023-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $52.68 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $51.48 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $45.50 | 2023-2025 | Crysvita |
| Becton, Dickinson and Company | $33.51 | 2021-2022 | |
| Medtronic, INC. | $32.70 | 2023 | Inpen Smart Insulin Delivery System |
| Sequel Med Tech, LLC | $31.84 | 2025 | Twiist |
| Radius Health, INC. | $31.40 | 2024 | Tymlos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.71 | 2024 | |
| Tolmar, INC. | $28.01 | 2023 | |
| Soleno Therapeutics, INC. | $28.01 | 2025 | Vykat Xr |
| Embecta Corp. | $23.40 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Astrazeneca Pharmaceuticals LP | $20.68 | 2023 | Farxiga |
| Verity Pharmaceuticals INC. | $19.91 | 2024 | Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.01 | 2022 | |
| Rgh Enterprises LLC | $17.60 | 2025 | |
| Currax Pharmaceuticals LLC | $16.96 | 2025 | Contrave |
| Cequr Corporation | $15.70 | 2023 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $14.64 | 2022 | |
| Lifescan, INC. | $14.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.